Why Medicine Is Slow to Change

Prof Pollack discusses Dr Semmelweis

Ignaz Semmelweis (1818-1865) was a Hungarian physician who suggested that doctors should start washing their hands in between examining corpses and delivering babies. At the time, there was a high mortality rate in obstetrical clinics and Dr Semmelweis suggested that if doctors started washing their hands before delivering babies, the mortality rate would be reduced. Dr Semmelweis did this and found, unsurprisingly to us, that the mortality rate for his patients was dramatically reduced. 

Despite this, Semmelweis’s doctor colleagues did not accept that washing hands was important, and they did not change their way of doing things. Understandably, Dr Semmelweis became very frustrated by his fellow doctor’s unwillingness to accept something that was just so obvious - especially because he had demonstrated with evidence that washing hands had a direct and dramatic impact on the survival of his own patients. The frustration associated with this literally sent Semmelweis mad and he died in a mental institution. 

It seems incredible to us now that doctors were so unwilling to change and accept something so obvious. But the reality is that this exact same thinking process is still with us today. Medicine and science are just as reluctant to consider new evidence as they were back then. In fact, change is actually even more difficult to effect today than it was when Semmelweis was alive. Today, not only does basic human psychology work against the prospect for change, but we now have huge commercial interests that actively silence anyone who comes up with a new idea, or anything that challenges their revenue. Added to this, most of the main media organisations are, at the highest level, connected with the commercial interests. 

The Sound of Your Body’s Cells Talking

Life is fundamentally electric. One of the many examples of this can be seen (or rather heard) in the way that cells communicate. In the short video below we can firstly hear the rather coarse sound from nerve cells that many scientists are familiar with. Because the spikes of the sound are about the same frequency of the human voice, we cannot recognise the detail that exists within the sound. However, when it is expanded (effectively slowed down) we can hear the fascinating intricacies of cell to cell communication.  

The understanding of the body electric is important because there is an urgent need for us to understand the types of exposure that are therapeutic and the kind that are harmful. 

Over a very short period of time, we have allowed ourselves to become bathed in electromagnetic fields that are billions of times greater than the background levels humans evolved in. We are told that there is nothing to worry about because the levels are still not high enough to cause a biological effect. 

However, we have known for decades that levels way below current exposure levels have a biological effect. In fact, some frequencies have been shown to have a therapeutic effect, for example against cancer - as explained by Professor Boris Pasche here.

So, what is healthy and what is detrimental? The Body Electric documentary asks the world leading experts what we know already.

EMF Hazards

Electromagnetic fields are a double-edged sword. They can be used appropriately for many therapeutic applications. But the indiscriminate, huge increase, in background levels of EMFs is certainly having an effect on biology.

Many health authorities state that there is no cause for concern below the thermal threshold. Suggesting that biological effects only occur if the exposure causes heating of tissues. However, biological effects of various kinds have been demonstrated 1000 times lower than the typical exposure associated with using a mobile phone.

A detailed investigation into how our bodies are affected, and at what frequencies/intensities, and what we can do to protect ourselves, and children, is overdue.

Your Circulation is Assisted by Light Energy.

The circulation of our blood through the capillaries is assisted not by the heart but instead by light energy.

To understand this, we must first consider the properties of water. Most people are aware that the human body is mostly made up of water. By volume, two thirds of our cells content is water. But because the water molecule is so small, a lot of water molecules are needed to make up this two thirds volume. And in fact, calculated in terms of the number of molecules, 99% of our bodies molecules are water molecules.

We tend to think of water as a basic every day substance. Although water is of course ubiquitous, there is certainly nothing mundane about it. Scientists like Professor Gerald Pollack at the University of Washington have been researching the properties of water for decades and they have made a number of incredible discoveries.

Humans can see less than 1% of the electromagnetic spectrum - might the other 99% also have important implications for health?


Treating Pain, Insomnia, Depression and Anxiety Without the Side Effects of Drugs

Alpha-Stim is a cranial electrotherapy stimulation (CES) device that has been clinically proven to be effective for treating pain, anxiety, insomnia, and depression, with very few or no side effects. It utilizes a microcurrent wave form that stimulates the brain's natural alpha rhythm.

Alpha-Stim can also be applied to various body sites to relieve joint and musculoskeletal pain. It is so safe and effective, that it is available over the counter in Europe, Asia, Australia, Canada and elsewhere. The United States is the only country that requires a prescription.

The justification for Alpha-Stim requiring a prescription is not clear, especially since the device has a very good record of safety and efficacy in the U.S. for over three decades. The Food and Drug Administration (FDA) has investigated it on numerous occasions during this period and have not uncovered anything to dispute this. It has been suggested that pressure from powerful drug manufacturers and others whose profits would be threatened may be responsible for denying greater availability to the public. Official documents and live recordings of FDA proceedings support this opinion.

To provide some background, when the FDA first began to regulate medical devices in 1976, it literally dumped many devices into the highest risk category (Class III), simply because it didn’t have sufficient information to process each application appropriately. The law required the FDA to review and appropriately reclassify those devices temporarily placed in Class III within 36 months. That was 40 years ago and this has still not been done!

Class III designation is for high risk devices like heart valve replacements. Electromedical Products Inc. (the makers of Alpha-Stim) strongly felt that they had more than enough data in over 125 clinical and 2 dozen animal studies to show that a lower risk categorization (Class II) was more appropriate and would make the treatment more readily available.

This led to a long running battle with the FDA, during which there were numerous events that hindered rather then helped to resolve this conflict. For example, Alpha-Stim is used widely within the U.S. military, but in a 2012 FDA meeting, one of the panel members tried to suggest that hardly anyone in the Army was using it. This was based on a conversation he had with a colonel at Walter Reed and allegedly "spent hours" in seeking to find information on the use of Alpha-Stim. In reality, the conversation could only have been for a few minutes, since it was during the break. He was unable to contact Dr. James Kelly, who heads the National Intrepid Center of Excellence (NICoE), who "has not used it." The fact is that at a 2011 NICoE meeting with Dr. Kelly and his senior staff, all were aware of Alpha-Stim, many had prescribed or used it on patients, family members and in a few instances, personally, with satisfactory results. One of these individuals was present at this FDA meeting but was prevented from testifying. In addition, none of the panel members had any personal experience with Alpha-Stim despite the fact that including such an individual was required for the proceedings.

In the first video clip, you can see these spurious comments and then the misinformation being corrected by a qualified Army Colonel with extensive military and personal practice experience with Alpha-Stim therapy.

Video 1 FDA Panel Member Tries to Misinform.

As can be seen, this appears not to have been an objective fact finding meeting, but rather a kangaroo court devoted to rubber stamping approval of a decision that had already been made. In the second video clip Dr. Jeffrey Marksberry discusses some of the Alpha-Stim double blind clinical trials studies currently in progress at Walter Reed (in contrast to the comments made by the FDA panel member) and other leading medical centers. A list of studies is available here.

Video 2 Dr. Jeff Marksberry

This is important, since other CES devices may not adhere to such rigid standards or obtain the same results. In addition, there are numerous copycat electrical stimulation devices that are applied to the skull and elsewhere that are much less expensive and do not require a prescription since they are generally regarded as safe. Although they make similar claims, they have no supportive studies and are not effective. Some describe themselves as CES devices, which is confusing to the public and possibly the FDA. Because they provide no benefit other than a transient placebo response, CES gets a bad reputation and the baby is thrown out with the bathwater.

The FDA's Center for Devices and Radiological Health (CDRH) had been severely criticized by Congressional Committes following a 2008 letter written on behalf of a large group of CDRH scientists and physicians who stated that CDRH managers had “corrupted and interfered with the scientific review of medical devices.” Six employees later sued the FDA, alleging that it had conducted surveillance of their communications without regard to their privacy rights under the law. A 2014 lengthy follow-up Congressional report repeatedly excoriated the FDA for intercepting communications between CDRH employees and members of Congress. In a letter to the FDA, Senator Charles Grassley Chairman of the Committee on the Judiciary, wrote, "It is absolutely unacceptable for the FDA to be spying on employees who reach out to members of Congress to expose abuses or wrongdoing in government agencies." Senator Grassley and House Oversight Committee Chairman Darrell Issa subsequently accused the FDA of "stonewalling" their investigation into the matter.

There may be some light at the end of the tunnel, since there have been some changes in CDRH leadership and the FDA Commissioner has promised a thorough internal investigation. Others believe that reclassification is more likely to remain in limbo because the Agency is not willing to admit its mistakes and continues to be influenced by powerful drug companies and others whose income is threatened. The Alpha-Stim experience is important since it helps to explain why this and other innovative electrical energy therapies are not more widely available, particularly in the U.S.

Could this be the Future of Cancer Treatment?

Doctors are using low-intensity electromagnetic fields to treat cancer patients, with the ability to specifically target cancer cells without damaging healthy tissue.

Professor Boris Pasche and colleagues have developed a novel treatment that uses very low intensity radiofrequency waves, modulated to target specific types of cancer. 

The treatment is administered via a TheraBionic device. 

It is based on the incredible finding that different types of cancer correspond to different frequencies. In this way, patients receive a prescription frequency corresponding to the type of cancer.

Currently, most of the research has been done with liver cancer patients (hepatocellular carcinoma). Liver cancer is a particularly difficult condition to treat - the very nature of the condition means that patients cannot tolerate the medications that might normally be used. 

With current available treatments, patients with hepatocellular carcinoma have a very limited life expectancy, ranging from 6-12 months. In the video clip below Professor Pasche explains how some patients have continued to survive for several years with the use of the TheraBionic device.

Professor Pasche has impeccable credentials, including: Charles L. Spurr Professor of Medicine, Chairman of the Department of Cancer Biology and Director of the Comprehensive Cancer Center at Wake Forest University Medical Center.  He is also Associate Editor, Hematology/Oncology and Cancer Genetics for The Journal of the American Medical Association.

Potential for Treating Other Types of Cancer

Professor Pasche and colleagues are focussed on the treatment of liver cancer for the purpose of current clinical trials, and to provide even more data on efficacy. However, during the development of the treatment, significant benefits have been seen in other types of cancer.

For example, Professor Paul Rosch has previously written:

"Treatment is completely safe, has no side effects, and can be administered by patients at home for 1 h, three times a day, during which they can watch TV or read. It consists of administering radiofrequency waves that are specific for this tumor by means of a spatula like device that is held in the mouth like a lollipop. It can also be programmed for other malignancies, and one patient with breast cancer that had metastasized to the adrenal gland and bone, had a “complete response” after an 11-month treatment. A patient with stage IV thyroid cancer metastatic to the lungs has received continuous treatment for more than 7 years. Because of this and subsequent developments, It seems likely that in the future, doctors will be prescribing frequencies, rather than pushing pills."

From Rosch, Paul J.. Bioelectromagnetic and Subtle Energy Medicine, Second Edition.


Targeting Cancer Cells, Leaving Healthy Tissue in Tact.

This type of specific radiofrequency treatment is particularly beneficial because it targets the cancer cells and not the healthy tissue. This specificity of the treatment has been confirmed using various experiments and by monitoring the patients blood tests.

In the second video (below) Hugo Jimenez, a researcher at Wake Forest University Medical Center, describes some of the ways that the team are investigating the mechanism of action.